Application of deferoxamine mesylate in preparing medicaments for treating postmenopausal osteoporosis
A technology for deferoxamine mesylate and osteoporosis, which is applied in the field of preparation of medicines for treating postmenopausal osteoporosis, and achieves the effects of less toxicity and reduced bone mass loss.
Active Publication Date: 2012-07-04
SUZHOU UNIV
View PDF1 Cites 4 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
There is no report on the study of deferoxamine m...
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
Embodiment
[0031] Example: According to the animal experiment results of deferoxamine mesylate in the treatment of postmenopausal osteoporosis, and the clinical medication method of deferoxamine mesylate, the present invention can use mesylate to treat postmenopausal osteoporosis. Ferricamine is slowly infused intravenously, 50mg / kg each time, 3 times a week.
[0032] The research results supporting this experiment are as follows:
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more PUM
Login to view more Abstract
The invention relates to application of deferoxamine mesylate, in particular to application of the deferoxamine mesylate in preparing medicaments for treating postmenopausal osteoporosis. The deferoxamine mesylate has low toxicity and safety and can greatly reduce the loss of postmenopausal bone mineral contents.
Description
[0001] technical field [0002] The invention relates to the use of deferoxamine mesylate, in particular to the use of deferoxamine mesylate in the preparation of medicines for treating postmenopausal osteoporosis. Background technique [0003] The chemical name of deferoxamine mesylate (DFO) is N-[5-[3-[(5-aminopentyl)-hydroxycarbamoyl]-propionamide]pentyl]-3-[[(5 -(N-glycolamide)pentyl]-carbamoyl]-propylene-methylsulfonic acid, the molecular formula is C 25 h 48 N 6 o 8 .CH 3 SO 3 H, the molecular weight is 656.8. Desferoxamine mesylate is a chelating agent, which mainly forms chelates with ferric ions and aluminum ions, and its chelate formation constants are 10, respectively. 31 and 10 25 , due to its chelating properties, no matter the free iron in the plasma or in the cells, it can be combined with it to form ferric amine chelate. Clinically, it is mainly used for the treatment of chronic iron overload, acute iron poisoning, and chronic...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more Application Information
Patent Timeline
Login to view more IPC IPC(8): A61K31/16A61P19/10
Inventor 徐又佳李凯李光飞高超俞晨
Owner SUZHOU UNIV
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Try Eureka
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap